Log in to save to my catalogue

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled res...

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled res...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7984727

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

About this item

Full title

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2018-01, Vol.19 (1), p.51-64

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundThe approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or metastatic urothelial carcinoma. Avelumab, a human monoclonal anti-PD-L1 antibody, has shown promising antitumour activity and safety in this disease. We aimed to assess the...

Alternative Titles

Full title

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7984727

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7984727

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(17)30900-2

How to access this item